P572: Evaluation of safety, pharmacokinetics and efficacy of oral treatment with OST-122 in patients with moderate to severe ulcerative colitis: A Phase Ib/IIa, randomized, double blind, placebo controlled clinical trialECCO'24Year: 2024
Authors: Barreiro-de Acosta, M.(1)*;Skybalo, S.(2);Rodríguez, C.(3);García-López, S.(4);Martín-Arranz, M.D.(5);Torrealba, L.(6);Iglesias-Flores, E.(7);Arguelles-Arias, F.(8);Ber, Y.(9);Shevchuk, V.(10);Castro-Fernandez, C.(11);Castro-Palomino, J.C.(11);Kurz, G.(11);Heredia, A.(11);
(1)University Hospital Santiago De Compostela CHUS, Department of Gastroenterology- IBD Unit, Santiago De Compostela, Spain;(2)Medical Center “Ok!Clinic” of International Institute of Clinical Research LLC, Gastroenterology, Kyiv, Ukraine;(3)Complejo Hospitalario Universitario de Navarra-, Gastroenterology Department, Pamplona, Spain;(4)Hospital Universitario Miguel Servet, Gastroenterology Department, Zaragoza, Spain;(5)Hospital Universitario La Paz, Gastroenterology Department, Madrid, Spain;(6)Hospital Josep Trueta, Gastroenterology Department, Girona, Spain;(7)Hospital Universitario Reina Sofía.UCO- IMIBICCórdoba, Gastroenterology Department, Córdoba, Spain;(8)Hospital Universitario Virgen Macarena. Universidad de Sevilla, Gastroenterology Department, Sevilla, Spain;(9)Hospital Universitario San Jorge, Gastroenterology Department, Huesca, Spain;(10)Medical and Diagnostic Center PE PMC @D@Acinus@D@, Gastroenterology Department, Kropyvnytskyi, Ukraine;(11)Oncostellae S.L, Oncostellae S.L, Santiago de Compostela, Spain;
P573: Simplified MARIA score does not predict long-term outcomes in Crohn’s disease patients undergoing modified side-to-side strictureplasty for extensive ileitisECCO'24Year: 2024
Authors: De Greef, I.(1)*;Bislenghi, G.(2);Lenfant, M.(1);Verstockt, S.(1);Terrasson, I.(2);Verstockt, B.(3);Sabino, J.(3);Ferrante, M.(3);Vanbeckevoort, D.(4);D@E@Hoore, A.(2);Vermeire, S.(3);
(1)KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(2)University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium;(3)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(4)University Hospitals Leuven, Department of Radiology, Leuven, Belgium;
P574: Clinical outcomes in extending of injection period of ustekinumab from every 8 to 12 weeks in patients with Crohn’s disease (CD-EXTEND Study)ECCO'24Year: 2024
Authors: Kato, S.(1)*;Tagawa, K.(1);Yamaga, N.(2);Yakabi, K.(2);Nagoshi, S.(2);
(1)Saitama Medical Centre- Saitama Medical University, Department of Gastroenterology and Hepatology- and Centre for Inflammatory Bowel Disease, Kawagoe City- Saitama, Japan;(2)Saitama Medical Centre- Saitama Medical University, Department of Gastroenterology and Hepatology, Kawagoe City- Saitama, Japan;
P575: Kono-S anastomosis reduces post-op intervention after ileocolic resection for Crohn’s diseaseECCO'24Year: 2024
Authors: Uchino, T.(1)*;Alipouriani, A.(1);Dominguez, O.H.(1);Hull, T.L.(1);Steele, S.R.(1);Cohen, B.(2);Lipman, J.(1);Holubar, S.D.(1);
(1)Cleveland Clinic, Colorectal Surgery, Cleveland, United States;(2)Cleveland Clinic, Gastroenterology- Hepatology & Nutrition, Cleveland, United States;
P576: Fecal calprotectin could predict clinical and endoscopic response to ustekinumab therapyECCO'24Year: 2024
Authors: BertaniMD, L.(1)*;Tricò, D.(2);Barberio, B.(3);Vernero, M.(4);Bretto, E.(4);Ceccarelli, L.(5);Pardi, V.(2);Calabrese, F.(6);Pasta, A.(6);Bertin, L.(3);Fabiana, Z.(3);Semprucci, G.(3);Bodini, G.(6);Ribaldone, D.G.(4);Savarino, E.V.(3);Costa, F.(5);
(1)Tuscany North-West ASL - Pontedera Hospital, General Surgery and Gastroenterology, Pontedera, Italy;(2)University of Pisa, Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy;(3)University of Padua, Surgical- Oncological and Gastroenterological Sciences, Padua, Italy;(4)University of Turin, Medical Sciences, Turin, Italy;(5)Pisa University Hospital, General Surgery and Gastroenterology, Pisa, Italy;(6)University of Genoa, Internal Medicine and Medical Specialities, Genoa, Italy;
P577: Histological Remission Leads to Less Endoscopic Flare-up in Moderate-to-Severe, Biologics Experienced Ulcerative Colitis Patients: A Comprehensive Retrospective Cohort StudyECCO'24Year: 2024
Authors: Wei, Z.H.(1)*;Le, P.H.(2,3,4);Chiu, H.Y.(1);Yeh, P.J.(3,5);Chiu, C.T.(2,3,4);Chiu, C.H.(3,6);
(1)Chang Gung University, School of Medicine, Taoyuan City, Taiwan;(2)Chang Gung Memorial Hospital- Linkou Branch, Department of gastroenterology and hepatology, Taoyuan City, Taiwan;(3)Chang Gung Memorial Hospital, Chang Gung Microbiota Therapy Center, Taoyuan City, Taiwan;(4)Taiwan Association of the Study of Small Intestinal Disease, Tassid, Taoyuan City, Taiwan;(5)Chang Gung Memorial Hospital- Linkou Branch, Division of Pediatric Gastroenterology- Department of Pediatrics, Taoyuan City, Taiwan;(6)Chang Gung Memorial Hospital- Linkou Branch, Division of Pediatric Infectious Diseases- Department of Pediatrics, Taoyuan City, Taiwan;
P578: CDST (Clinical Decision Support Tool) is predictive of steroid-free clinical remission in patients with Crohn@E@s disease treated with vedolizumab in a specific manner which is mainly driven by the serum level of albumin.ECCO'24Year: 2024
Authors: Buisson, A.(1)*;Nancey, S.(2);Dodel, M.(1);Gay, C.(2);Coban, D.(1);Bazoge, M.(1);Pereira, B.(1);Boschetti, G.(2);
(1)CHU Clermont-Ferrand, IBD Unit, Clermont-Ferrand, France;(2)HCL, IBD Unit, Lyon, France;
P579: Dietary beliefs, barriers, and acceptability of diet in IBD patients – a multi-centre survey from the Asia-Pacific regionECCO'24Year: 2024
Authors: Tay, S.(1)*;Chan, P.W.W.(1);Wei, S.C.(2);Tan, M.(1);Hilmi, I.N.(3);Leong, J.W.H.(1);Tan, Y.Y.(1);Lim, C.T.(1);Ling, K.L.(4);Tey, T.T.(5);Tan, C.K.(6);Leong, R.W.L.(7);Lim, W.C.(8);Hartono, J.L.(9);Shim, H.H.(1);Ong, D.(4);Ooi, C.J.(10);Salazar, E.(1);
(1)Singapore General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore;(2)National Taiwan University Hospital, Department of Internal Medicine, Taipei, Taiwan;(3)University of Malaya, Division of Gastroenterology and Hepatology- Department of Medicine, Kuala Lumpur, Malaysia;(4)Mount Elizabeth Medical Centre, nil, Singapore, Singapore;(5)Sengkang General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore;(6)Changi General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore;(7)Concord Repatriation General Hospital, Gastroenterology and Liver Services, Sydney- New South Wales, Australia;(8)Tan Tock Seng Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore;(9)National University Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore;(10)Gleneagles Medical Centre, nil, Singapore, Singapore;
P580: Iron deficiency anaemia and quality of life in Inflammatory Bowel Disease: Prospective cohort study of ferric derisomaltose on quality of life and work productivity in patients with IBDECCO'24Year: 2024
Authors: Goodhand, J.R.(1);Parkinson, M.(2);Bewshea, C.(2);Ahmad, T.(1);Kennedy, N.A.(1,3)*;
(1)Royal Devon University Healthcare NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;(2)University of Exeter, Exeter IBD Research Group, Exeter, United Kingdom;(3)University of Exeter, Exeter BRC, Exeter, United Kingdom;
P581: Age-related patterns in biological therapy use and surgery among patients with IBD: Insights from the Belgian PANTHER cohortECCO'24Year: 2024
Authors: Celis, J.(1)*;Truyens, M.(2);Verstockt, S.(3);Glorieus, E.(2);De Wolf, M.(4);Lenfant, M.(3);Barbaraci, M.(4);Sabino, J.(3);Ferrante, M.(5);Geldof, J.(2);Verstockt, B.(5);Laukens, D.(1);Cleynen, I.(6);Vandermeulen, L.(4);Vermeire, S.(5);Lobaton, T.(2);
(1)Ghent University, Internal Medicine and Pediatrics, Ghent, Belgium;(2)University Hospital of Ghent, Gastroenterology, Ghent, Belgium;(3)KU Leuven, Chronic Diseases and Metabolism CHROMETA, Leuven, Belgium;(4)Universitair Ziekenhuis Brussel UZ Brussel, Gastroenterology, Brussels, Belgium;(5)University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium;(6)KU Leuven, Human Genetics, Leuven, Belgium;IBD Research Unit
P582: Combination of granulocyte–monocyte apheresis and ustekinumab: multicentre and retrospective studyECCO'24Year: 2024
Authors: Rodríguez-Lago, I.(1)*;Herrera-deGuise, C.(2);Boscá-Watts, M.(3);Rodríguez, C.(4);Leo, E.(5);Calvo, M.(6);Cañete, F.(7);Chacón, S.(8);Cuarán, C.(9);Elorza, A.(1);Guerra, E.(10);Iglesias, E.(11);Sánchez, D.(12);Barreiro-de Acosta, M.(13);Ginard, D.(14);Cabriada, J.L.(1);
(1)Hospital Universitario de Galdakao, Gastroenterology Department, Galdakao, Spain;(2)Hospital Universitari Vall d@E@Hebron, Gastroenterology Department, Barcelona, Spain;(3)Hospital Clínico Universitario de Valencia, Gastroenterology Department, Valencia, Spain;(4)Hospital Universitario de Navarra, Gastroenterology Department, Pamplona, Spain;(5)Hospital Universitario Virgen del Rocío, Gastroenterology Department, Sevilla, Spain;(6)Hospital San Pedro, Gastroenterology Department, Logroño, Spain;(7)Hospital Universitari Germans Trias i Pujol, Gastroenterology Department, Badalona, Spain;(8)Hospital General Universitario Morales Meseguer, Gastroenterology Department, Murcia, Spain;(9)Hospital Universitario Miguel Servet, Gastroenterology Department, Zaragoza, Spain;(10)Hospital Universitario de Gran Canaria Dr. Negrín, Gastroenterology Department, Las Palmas, Spain;(11)Hospital Universitario Reina Sofía, Gastroenterology Department, Córdoba, Spain;(12)Hospital Universitario Virgen de las Nieves, Gastroenterology Department, Granada, Spain;(13)Hospital Clínico Universitario de Santiago, Gastroenterology Department, Santiago de Compostela, Spain;(14)Hospital Universitario Son Espases, Gastroenterology Department, Palma, Spain;
P583: Infliximab Monitoring in Crohn@E@s Disease and Development of Neural Networks Using Clinical Variables to Predict Disease Activity and ImmunogenicityECCO'24Year: 2024
Authors: Gomes, L.E.M.(1);Genaro, L.M.(1)*;Castro, M.M.(1);Pascoal, L.B.(1);Ricci, R.L.(1);Silva, F.B.C.(1);Camargo, M.G.(1);Bonfitto, P.H.L.(1);Ayrizono, M.L.S.(1);Azevedo, A.T.(2);Leal, R.F.(1);
(1)Inflammatory Bowel Disease Research Laboratory- Gastrocenter- Colorectal Surgery Unit- School of Medical Sciences- University of Campinas Unicamp, Department of Surgery, Campinas, Brazil;(2)Simulation Laboratory- School of Applied Sciences- University of Campinas Unicamp, Simulation Laboratory, Limeira, Brazil;
P584: Complication rates after two-stage vs three-stage restorative proctocolectomy with ileoanal pouch construction in the era of biologicsECCO'24Year: 2024
Authors: Doyon , F.(1);Saifi , M.(1)*;Doyon , A.(2);Kienle , P.(1);
(1)Theresienkrankenhaus und Diako gGmbH, General and Visceral Surgery, Mannheim, Germany;(2)University Hospital Heidelberg, Center for Pediatrics and Adolescent Medicine, Heidelberg, Germany;
P585: Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab FailureECCO'24Year: 2024
Authors: Bae, J.H.(1);Park, J.B.(1);Baek, J.E.(1);Hong, S.W.(1);Park, S.H.(1,2);Yang, D.H.(1);Ye, B.D.(1,2);Byeon, J.S.(1);Myung, S.J.(1);Yang, S.K.(1,2);Hwang, S.W.(1,2)*;
(1)University of Ulsan College of Medicine- Asan Medical Center, Department of Gastroenterology and Internal medicine, Seoul, Korea- Republic Of;(2)University of Ulsan College of Medicine- Asan Medical Center, Inflammatory Bowel Disease Center, Seoul, Korea- Republic Of;
P586: Influence of HLA-DQA1∗05 on the loss of response to anti-TNF treatment in inflammatory bowel disease. Spanish cohort of real clinical practice.ECCO'24Year: 2024
Authors: Pérez Pérez, J.(1)*;Escobar Ortiz, J.(1);Franco Moreno, A.I.(2);Plaza Santos, M.D.R.(1);Castillo Pradillo, M.(1);Ponferrada Díaz, Á.(1);
(1)Infanta Leonor University Hospital, Gastroenterology and Hepatology, Madrid, Spain;(2)Infanta Leonor University Hospital, Internal Medicine, Madrid, Spain;
P587: Development and Characterization of a Novel Extended Half-life Monoclonal Antibody Drug Candidate Targeting Integrin ɑ4β7 for the Treatment of IBDECCO'24Year: 2024
Authors: Zhu, E.(1);Rios, D.(2);Vaz, R.(3);Friedman, J.(4)*;Nguyen, D.(5);Spencer, A.(6);Shaheen, H.(7);Oh, J.(2);
(1)Paragon Therapeutics, Biotherapeutics Discovery, Waltham- MA, United States;(2)Paragon Therapeutics, Biology, Waltham- MA, United States;(3)Paragon Therapeutics, Program and Alliance Management, Waltham- MA, United States;(4)Spyre Therapeutics, Clinical Development, Ardmore, United States;(5)Spyre Therapeutics, Clinical Development, Waltham- MA, United States;(6)Spyre Therapeutics, Nonclinical Development, Waltham- MA, United States;(7)Paragon Therapeutics, Research, Waltham- MA, United States;
P588: Evolution and management of inflammatory joint pathology with non-anti-TNF therapies in inflammatory bowel diseaseECCO'24Year: 2024
Authors: Gonzalez Diaz, I.(1)*;Suarez Ferrer , C.(2);Plasencia Rodriguez, C.(3);Gutierrez, M.(3);Rueda Garcia , J.L.(2);Martin-Arranz, E.(2);Poza Cordon, J.(2);Sanchez-Azofra, M.(2);Amor Costa , C.(1);Amiama Roig, C.(1);Martin-Arranz, M.D.(4);
(1)Hospital La Paz, Gastroenterology and Hepatology, Madrid, Spain;(2)Hospital La Paz Institute for Health Research – IdiPAZ La Paz University Hospital, Gastroenterology and Hepatology, Madrid, Spain;(3)Hospital La Paz, Rheumatologist, Madrid, Spain;(4)Hospital La Paz Institute for Health Research – IdiPAZ La Paz University Hospital – Universidad Autónoma de Madrid, Gastroenterology and Hepatology, Madrid, Spain;
P589: Real-world data on upadacitinib in the treatment of inflammatory bowel disease: safe and highly effective with extremely positive patient feedbackECCO'24Year: 2024
Authors: Harris, C.(1)*;Gee, T.(1);Barcan, A.(2);Yanagisawa, Y.(2);Brown, M.(2);Gordon, J.N.(1);
(1)Hampshire Hospitals NHS Foundation Trust Royal Hampshire County Hospital, Gastroenterology, Winchester, United Kingdom;(2)Hampshire Hospitals NHS Foundation Trust Basingstoke and North Hampshire Hospital, Gastroenterology, Basingstoke, United Kingdom;
P590: Use of upadacitinib in Refractory Paediatric Inflammatory Bowel Diseasein: A Single-Center Cohort StudyECCO'24Year: 2024
Authors: Potapov, A.(1)*;Vinokurova , A.(2);Pushkareva , A.(3);Prokhorenkova, M.(3);Anushenko , A.(4);Fisenko, A.(5);
(1)National Medical Research Center for Childrens Health, Department of Gastroenterology, Moscow, Russian Federation;(2)National Medical Research Center for Children@E@s Health- -, Department of Gastroenterology, Moscow, Russian Federation;(3)I.M. Sechenov First Moscow State Medical University Sechenov University, Department of Pediatrics and Pediatric Rheumatology, Moscow, Russian Federation;(4)National Medical Research Center for Children@E@s Health, Department of Gastroenterology, Moscow, Russian Federation;(5)National Medical Research Center for Children@E@s Health, director, Moscow, Russian Federation;
